Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
申请人:Glenmark Pharmaceuticals S.A.
公开号:US08129401B2
公开(公告)日:2012-03-06
The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.
本发明涉及式(1)及其类似物、互变异构体、对映异构体、立体异构体、区域异构体、多晶形态、药学上可接受的盐、适当的N-氧化物、药学上可接受的溶剂化物及其制备的药物组合物。该组合物可用于治疗过敏和炎症性疾病,包括哮喘、慢性支气管炎、特应性皮炎、荨麻疹、过敏性鼻炎、过敏性结膜炎、春季结膜炎、嗜酸性肉芽肿、
银屑病、类风湿性关节炎、感染性休克、溃疡性结肠炎、克隆氏病、心肌再灌注损伤和脑再灌注损伤、慢性肾小球肾炎、内毒素性休克和成人呼吸窘迫综合征。